Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

被引：0
|
作者：
Septiara Putri
Ery Setiawan
Siti Rizny F. Saldi
Levina Chandra Khoe
Euis Ratna Sari
Amila Megraini
Mardiati Nadjib
Sudigdo Sastroasmoro
Armansyah Armansyah
机构：
[1] University of Indonesia,Health Policy and Administration Department, Faculty of Public Health
[2] Center for Health Economics and Policy Studies (CHEPS) University of Indonesia,Community Medicine Department
[3] Center for Clinical Epidemiology and Evidence Based Medicine (CEEBM) Cipto Mangunkusomo Hospital,Center for Health Financing and Insurance
[4] Faculty of Medicine University of Indonesia,undefined
[5] Indonesian Health Technology Assessment Committee,undefined
[6] Ministry of Health Republic of Indonesia,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
Rituximab; Lymphoma; DLBCL; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
    Putri, Septiara
    Setiawan, Ery
    Saldi, Siti Rizny F.
    Khoe, Levina Chandra
    Sari, Euis Ratna
    Megraini, Amila
    Nadjib, Mardiati
    Sastroasmoro, Sudigdo
    Armansyah, Armansyah
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [2] THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
    Zhao, M. M.
    Xiang, Y.
    Juying, W.
    Jia, S. H.
    Chen, B. B.
    Fan, C. S.
    [J]. VALUE IN HEALTH, 2019, 22 : S455 - S455
  • [3] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [4] Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed With Diffuse Large B-Cell Lymphoma
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Dreyling, Martin H.
    Danese, Mark D.
    [J]. CANCER, 2012, 118 (24) : 6079 - 6088
  • [5] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    [J]. HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [6] COST-EFFECTIVENESS AND COST-UTILITY ANALYSES OF POLATUZUMAB VEDOTIN WITH RITUXIMAB AND CHEMOTHERAPY VS RITUXIMAB AND CHEMOTHERAPY IN TREATING NAIVE DIFFUSE LARGE B-CELL LYMPHOMA IN ITALY
    Bellone, M.
    Pradelli, L.
    Ghislieri, D.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S75 - S76
  • [7] IMPACT OF RITUXIMAB ON OUTCOMES OF VERY ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Lee, L.
    Khor, S.
    Hoch, J. S.
    Luo, J.
    Bremner, K.
    Krahn, M.
    Crump, M.
    Hodgson, D. C.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 195 - 195
  • [8] Evaluation of the impact of maintenance rituximab in elderly patients with diffuse large B-cell lymphoma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 456 - 457
  • [9] Rituximab and Bendamustin in patients with diffuse large B-cell lymphoma not eligible for CHOP like chemotherapy
    Kuntz, E.
    Schmitt, T.
    Dietrich, S.
    Bonn, S.
    Ho, A. D.
    Witzens-Harig, M.
    [J]. ONKOLOGIE, 2010, 33 : 47 - 47
  • [10] Microcosting and Budget Impact Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
    Painschab, Matthew
    Kohler, Racquel E.
    Gopal, Satish
    [J]. BLOOD, 2018, 132
12345